ATA901092A - Teilchen enthaltend biologisch aktives peptid - Google Patents

Teilchen enthaltend biologisch aktives peptid

Info

Publication number
ATA901092A
ATA901092A AT0901092A AT901092A ATA901092A AT A901092 A ATA901092 A AT A901092A AT 0901092 A AT0901092 A AT 0901092A AT 901092 A AT901092 A AT 901092A AT A901092 A ATA901092 A AT A901092A
Authority
AT
Austria
Prior art keywords
biodically
containing particles
active peptide
peptide containing
active
Prior art date
Application number
AT0901092A
Other languages
English (en)
Other versions
AT410896B (de
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27202407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA901092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ATA901092A publication Critical patent/ATA901092A/de
Application granted granted Critical
Publication of AT410896B publication Critical patent/AT410896B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
AT0901092A 1991-04-19 1992-04-16 Teilchen enthaltend biologisch aktives peptid AT410896B (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4112854 1991-04-19
DE4113016 1991-04-20
DE4113343 1991-04-24
PCT/EP1992/000862 WO1992018105A1 (en) 1991-04-19 1992-04-16 Improvements in pharmaceutical compositions

Publications (2)

Publication Number Publication Date
ATA901092A true ATA901092A (de) 2003-01-15
AT410896B AT410896B (de) 2003-08-25

Family

ID=27202407

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0901092A AT410896B (de) 1991-04-19 1992-04-16 Teilchen enthaltend biologisch aktives peptid

Country Status (16)

Country Link
EP (1) EP0580690B2 (de)
JP (1) JP3695754B2 (de)
AT (1) AT410896B (de)
AU (1) AU1577992A (de)
CA (1) CA2108018C (de)
DE (1) DE4291156T1 (de)
ES (1) ES2069995T5 (de)
FR (1) FR2675382B1 (de)
GB (1) GB2269536B (de)
IE (1) IE921230A1 (de)
IL (1) IL101635A0 (de)
IT (1) IT1254323B (de)
MX (1) MX9201782A (de)
NO (1) NO933695D0 (de)
WO (1) WO1992018105A1 (de)
ZA (1) ZA922834B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
ES2172574T5 (es) * 1993-11-19 2012-11-29 Alkermes, Inc. Preparación de micropartículas biodegradables que contienen un agente biológicamente activo
WO1996025918A1 (en) 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
ES2257041T3 (es) 1998-03-30 2006-07-16 Jagotec Ag Composicion y metodo para preparar microparticulas de substancias insolubles en agua.
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
DE69914742T2 (de) 1998-05-29 2004-11-25 Skyepharma Canada Inc., Verdun Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
ID29270A (id) 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
EA017290B1 (ru) 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона
CA2669392C (en) 2006-11-17 2016-05-10 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
JP2010510988A (ja) 2006-11-28 2010-04-08 マリナス ファーマシューティカルズ ナノ粒子製剤とその製造方法およびその利用
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
KR20180082457A (ko) 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
KR20220134529A (ko) 2019-12-06 2022-10-05 마리누스 파마슈티컬스 인코포레이티드 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1532993A (en) * 1975-03-07 1978-11-22 Beecham Group Ltd Injectable antibiotic compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US5002940A (en) * 1984-11-06 1991-03-26 Ciba-Geigy Corporation Solid drug formulations and stable suspensions
CH673395A5 (de) * 1987-01-30 1990-03-15 Ciba Geigy Ag
CA1323306C (en) * 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
US4963362A (en) † 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
GB2230440B (en) † 1989-02-09 1993-05-19 Sandoz Ltd Novel cyclosporin galenic forms

Also Published As

Publication number Publication date
CA2108018C (en) 2003-04-15
EP0580690B2 (de) 2000-09-13
ZA922834B (en) 1993-10-18
WO1992018105A1 (en) 1992-10-29
ITRM920281A1 (it) 1993-10-16
CA2108018A1 (en) 1992-10-20
IT1254323B (it) 1995-09-14
GB2269536A (en) 1994-02-16
JP3695754B2 (ja) 2005-09-14
AU1577992A (en) 1992-11-17
AT410896B (de) 2003-08-25
FR2675382B1 (fr) 1995-05-12
IE921230A1 (en) 1992-10-21
JPH06506926A (ja) 1994-08-04
DE4291156T1 (de) 1994-10-20
NO933695D0 (no) 1993-10-14
ES2069995T5 (es) 2000-11-16
FR2675382A1 (fr) 1992-10-23
MX9201782A (es) 1992-10-01
GB2269536B (en) 1995-05-10
IL101635A0 (en) 1992-12-30
GB9319585D0 (en) 1993-12-15
ITRM920281A0 (it) 1992-04-16
ES2069995T3 (es) 1995-05-16
EP0580690B1 (de) 1995-03-15
EP0580690A1 (de) 1994-02-02

Similar Documents

Publication Publication Date Title
ATA901092A (de) Teilchen enthaltend biologisch aktives peptid
DE4393381T1 (de) Peptide
NO942066D0 (no) Peptidderivater
DE69129395T2 (de) Antimikrobielle Peptide
DK6893D0 (da) Peptid
DE69315842T2 (de) Peptidverbindungen
FI941398A0 (fi) Modifioituja peptidijohdannaisia
DE69332485D1 (de) Immunmodulierende peptide
DK0589843T3 (da) Cyclosporinholdige farmaceutiske præparater
FI940945A (fi) Uusia isosteerisiä peptidejä
DE69220397D1 (de) Antimikrobielles Peptid und antimikrobieller Wirkstoff
SE8803847A0 (sv) Neuromodulerande peptid
DE69223844D1 (de) Antimikrobielles Peptid und antimikrobieller Wirkstoff
DK499886A (da) Peptid
DK197989A (da) Peptidanaloger
NO933097D0 (no) Insektisid virksomme peptider
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
FI944428A0 (fi) Viruksen vastaisia peptidejä
DE69314120D1 (de) Phospholipase c hemmendes peptid
NO177858C (no) Peptid
NO920903L (no) Flunarizinholdige anti-neoplastiske preparater
LV10286A (lv) Peptidu savienojumi
NO933613D0 (no) Lipidholdige proteinpartikler
LV10287A (lv) Peptidu savienojumi
FI942898A (fi) Terapeuttisesti aktiiviset peptidiyhdisteet

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee